Filing Details

Accession Number:
0000947871-17-000698
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-09-05 22:27:56
Reporting Period:
2017-08-31
Accepted Time:
2017-09-05 21:27:56
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1192448 Glaukos Corp GKOS () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1055949 D Samuel Isaly 601 Lexington Avenue
54Th Floor
New York NY 10022
Yes No No No
1055951 Orbimed Advisors Llc 601 Lexington Avenue
54Th Floor
New York NY 10022
Yes No No No
1432241 Orbimed Capital Gp Iii Llc 601 Lexington Avenue
54Th Floor
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.01 Per Share Disposition 2017-08-31 44,498 $37.82 1,358,833 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-08-31 424 $37.82 12,945 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-09-01 109,040 $37.72 1,249,793 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-09-01 1,038 $37.72 11,907 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-09-05 173,349 $37.94 1,076,444 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-09-05 1,651 $37.94 10,256 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-09-05 189,792 $39.63 886,652 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-09-05 1,808 $39.63 8,448 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-09-05 58,047 $40.77 828,605 No 4 S Indirect See Footnotes
Common Stock, Par Value $0.01 Per Share Disposition 2017-09-05 553 $40.77 7,895 No 4 S Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
No 4 S Indirect See Footnotes
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were sold in multiple transactions at prices ranging from $37.75 to $37.83 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  2. These Shares were sold in a block order at a price of $37.72.
  3. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $37.75 to $38.04 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $39.33 to $40.30 inclusive. Upon request, the Reporting Person undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These Shares were sold in multiple transactions at prices ranging from $40.33 to $41.22 inclusive. Upon request, the Reporting Person undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares sold at each separate price within the range set forth in this footnote.
  6. These Shares are held of record by OrbiMed Private Investments III, LP ("OPI III"). OrbiMed Capital GP III LLC ("GP III") is the general partner of OPI III, and OrbiMed Advisors LLC ("Advisors") is the managing member of GP III. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, GP III, Advisors and Isaly may be deemed to have voting and investment power over the securities held by OPI III and as a result may be deemed to have beneficial ownership over such securities.
  7. These Shares are held of record by OrbiMed Associates III, LP ("Associates III"). Advisors is the general partner of Associates III. Isaly is the managing member of and owner of a controlling interest in Advisors. By virtue of such relationships, Advisors and Isaly may be deemed to have voting and investment power over the securities held by Associates III and as a result may be deemed to have beneficial ownership over such securities.
  8. This report on Form 4 is jointly filed by GP III, Advisors, and Isaly. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. The Reporting Persons have designated a representative, currently Jonathan T. Silverstein, a member of Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.